She received her Bachelor of Science degree from Pennsylvania State University and her Masters of Business Administration degree from Saint Joseph's University. Julie currently serves on the Board of Visitors for the Smeal College of Business of the Pennsylvania State University, the Board of Directors for the Nathaniel Adamczyk Foundation and was 2009 Chairman of the Board of Directors for the Pennsylvania Biotechnology Association. McHugh held marketing positions of increasing scope and accountability at Astra-Merck, Rhone-Poulenc Rorer (Sanofi Aventis) and SmithKline (GlaxoSmithKline).
Before that she was President of Centocor, Inc., a J&J company. Her last role at J&J was Company Group Chairman for the Global Virology Business Unit. Before joining Nora, she held senior positions at Johnson & Johnson during a twelve year period. McHugh was president and CEO for Nora Therapeutics, a venture capital backed biotech start-up developing novel therapies to prevent implantation failure in the setting of in-vitro fertilization and recurrent pregnancy loss. CHADDS FORD, Pa., March 12 /PRNewswire-FirstCall/ - Endo Pharmaceuticals (Nasdaq: ENDP) announced today the appointment of Julie McHugh as the company's chief operating officer, effective March 15, 2010.
0 kommentar(er)
